COVID-19 Funding Opportunities

COVID-19 Research Grants for Combating the coronavirus crisis

As the COVID-19 situation continues to develop, EGC will maintain an updated list of relevant funding opportunities here. Click below to be notified as new COVID-19 research grants are announced.

Funding Agencies (Click to jump to agency)

I. Biomedical Advanced Research and Development Authority (BARDA)
II. Centers for Disease Control and Prevention (CDC)
III. National Institutes of Health (NIH)
IV. National Science Foundation (NSF)
V. Other US Funding Agencies
VI. International Opportunities

I. Biomedical Advanced Research and Development Authority (BARDA)

BARDA has updated its Broad Agency Announcements (BAAs) to focus exclusively on addressing the COVID-19 threat.  BARDA, with a total budget of $512 Million, is seeking proposals through the following mechanisms:


View Solicitation

Topic: Products to diagnose, prevent or treat novel coronavirus infections
Due Date: Rolling, through 10/31/2020
Budget: Unlimited

Division of Research, Innovation & Ventures (DRIVe) BAA

View Solicitation

Topics: Diagnostic assays, screening and model development, vaccines, advanced manufacturing.

Due Date: Abstract submissions due by 5PM ET on 6/30/2020.
Budget: $750,000


Request CoronaWatch Meeting

While CoronaWatch is not a direct funding mechanism, the U.S. government seeks information from stakeholders on available medical countermeasures in development for COVID-19. A CoronaWatch meeting is held by interactive webinar, in which the presenting team displays slides and engages with government personnel.  A CoronaWatch meeting is encouraged prior to applying for BARDA funding, so that organizations can better align their product development with government priorities.

II. Centers for Disease Control and Prevention (CDC)

The Centers for Disease Control and Prevention (CDC) and the National Institutes of Health (NIH) have released several funding opportunities focused on COVID-19.

CDC: Strengthening Public Health Systems and Services through National Partnerships to Improve and Protect the Nations Health

View Solicitation

Topic: Building capacity in the following emergency/crisis response areas: Incident Management for Early Crisis Response, Jurisdictional Recovery, Biosurveillance, Information Management, Mitigation, Surge Management, Communications.

Due Date: 4/2/2020
Budget: $300,000 – $3,000,000

III. National Institutes of Health (NIH)

Notices of Special Interest (NOSI)

Multiple NIH Institutes have issued a Notice of Special Interest (NOSI) to provide funding for Administrative Supplements on research topics related to COVID-19.  To be eligible for these Supplements, the applicant must have an active award through the Institute with sufficient time remaining to complete all studies proposed.

National Heart, Lung, Blood Institute (NHLBI)

Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19)

View Solicitation

Topic: NHLBI is issuing this Notice of Special Interest (NOSI) to highlight the urgent need for research on Coronavirus Disease 2019 (COVID-19) and on biological effects of its causative agent, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Topics of specific interest to NHLBI include host response, associations with heart, lung, and blood (HLB) diseases, potential impacts on transfusion safety, and clinical outcomes of infected individuals.

Due Date: Rolling, through 10/5/2020
Budget: Not specified

National Institute of Allergy and Infectious Diseases (NIAID)

NOSI regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19)

View Solicitation

Topics: Viral natural history, pathogenicity, transmission, as well as projects developing medical countermeasures and suitable animal models for pre-clinical testing of vaccines and therapeutics against SARS-CoV-2/COVID-19.

Due Date: Rolling until 3/25/2021
Budget: Not Specified

National Institute of General Medical Sciences (NIGMS)

NOSI regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2

View Solicitation


  • Incorporation of data related to SARS-CoV-2 into ongoing research efforts to develop predictive models for the spread of SARS-CoV-2 and other related infectious agents (all relevant grants).
  • Repurposing or modification of diagnostic tools currently under development to enable rapid detection of SARS-CoV-2 infection (SBIR/STTR grants only).
  • Rapid development of potential therapeutic agents for COVID-19 (SBIR/STTR only).

Due Date: Rolling, through 2/6/2021
Budget: Not Specified

National Center for Advancing Translational Sciences (NCATS)

NOSI: Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Heath Need

View Solicitation

Topics: Use of informatics solutions to diagnose cases and the use of CTSA-supported core resources (e.g., advanced scientific instruments, highly-specialized facilities, and regulatory expertise) to facilitate research on COVID-19 and advance the translation of research findings into diagnostics, therapeutics, and vaccines.

Eligible applicants are encouraged to apply through the following FOA’s:

PA-18-591 – Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Due Dates:

  • 5/4/2020
  • 11/2/2020

Budget: Application budgets are limited to no more than the amount of the current parent award and must reflect the actual needs of the proposed project.

PAR-19-099 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative Innovation Award (U01 Clinical Trial Optional)

Due Dates:

  • 7/10/2020
  • 11/9/2020
  • 3/8/2021
  • 7/9/2021

Budget: $400,000 – $750,000

PAR-19-100 – Limited Competition: Clinical and Translational Science Award (CTSA) Program: Exploratory Collaborative Innovation Awards (R21 Clinical Trial Optional)

Due Dates:

  • 7/10/2020
  • 11/9/2020
  • 3/8/2021
  • 7/9/2021

Budget: The combined budget for direct costs for the two-year project period may not exceed $275,000.

PAR-19-337 – Limited Competition: Competitive Revision Awards for the Clinical and Translational Science Award (CTSA) Program (U54 Clinical Trial Optional).

Due date: 9/25/2020
Budget: Budgets are limited to no more than $750,000/year in direct costs excluding consortium/contractual F&A costs.

Notice of Special Interest (NOSI): Repurposing Existing Therapeutics to Address the 2019 Novel Coronavirus Disease (COVID-19)

View Solicitation

Topics: Using innovative processes to identify the therapeutic/indication pair for use to treat COVID-19.

Eligible applicants are encouraged to apply through the following FOA’s:

PAR-17-465 – Bench Testing Therapeutic/Indication Pairing Strategies (UG3/UH3)

Due Dates: 6/26/2020
Budget: Up to $200,000 direct costs/year for UG3 proposals and up to $100,000 direct costs for UH3 proposals.

PA-18-462 – Clinical Trial Planning: Therapeutic/Indication Pairing Strategies (U34) (Clinical Trial Not Allowed)

Due Dates:

  • 6/16/2020
  • 10/16/2020

Budget: Maximum budget of $225,000 in direct costs.

PAR-18-332 – Clinic Testing Therapeutic/Indications Pairing Strategies (U01 Clinical Trial Required)

Due Dates:

  • 6/5/2020
  • 10/5/2020

Budget: Maximum budget of $3,000,000 in direct costs per year.

National Institute of Environmental Health Sciences (NIEHS)

NOSI: NIEHS Worker Training Program Coronavirus and Infectious Disease Response Training (Admin Supp Clinical Trial Not Allowed)

View Solicitation

Topics: Support worker-based training to prevent and reduce exposure of hospital employees, emergency first responders, and other workers who are at risk of exposure to Coronavirus through their work duties.

Eligible applicants are encouraged to apply through the following FOA’s:

PA-20-135 – Emergency Competitive Revision to Existing NIH Awards (Emergency Supplement – Clinical Trial Optional)

Due Dates: 4/24/2020
No Limit

National Institute of Drug Abuse (NIDA)

Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus

View Solicitation

Topic: NIDA is interested in research collecting and examining data on the risks and outcomes for COVID-19 infection in individuals suffering from substance use disorders.

Due Date: Rolling, through 3/31/2021
Budget: Maximum of $100,000 direct costs per year for 2 years.  Higher budgets may be considered with justification.

IV. National Science Foundation (NSF)

Dear Colleague Letter: Request for SBIR/STTR Phase I Proposals Addressing COVID-19

NSF is seeking Phase I SBIR/STTR proposals focused on the development and deployment of new technologies, products, processes, and services with the potential to positively impact the nation’s and world’s ability to respond to the COVID-19 crisis.

View Letter

Topics: Artificial intelligence, digital health, diagnostics, distributed ledger, environmental technologies, medical devices, pharmaceutical technologies, disinfection and sterilization, and filtration and separations.

Due Date: Rolling, Project Pitch submission required. NSF is committed to expediting review, with the hope of granting awards within 6 weeks of proposal receipt.
Budget: $225,000

Dear Colleague Letter on the Coronavirus

View Letter

The NSF encourages investigators to use existing NSF funding mechanisms to submit proposals to conduct non-medical, non-clinical-care research that can be used immediately to explore how to model and understand the spread of COVID-19, to inform and educate about the science of virus transmission and prevention, and to encourage the development of processes and actions to address this global challenge.

For proposals of up to $200K, NSF encourages using the Rapid Response Research (RAPID) funding mechanism, which allows NSF to receive and review proposals having a severe urgency.

Dear Colleague Letter: Provisioning Advanced Cyberinfrastructure to Further Research on the Coronavirus Disease 2019 (COVID-19)

View Letter

The Office of Advanced Cyberinfrastructure (OAC) within the Directorate for Computer and Information Science and Engineering is inviting RAPID proposals and supplemental funding requests to existing awards that address COVID-19 challenges through data and/or software infrastructure development activities.

V. Other US Funding Agencies

Medical Technology Enterprise Consortium (MTEC)

MTEC-20-09-COVID-19_Treatment_MIDRP “Development of Treatments for COVID-19”

MTEC is an enterprise partnership in collaboration with industry and academia to facilitate research and development activities, in cooperation with the U.S. Army Medical Research and Development Command (USAMRDC) and other DoD agencies in the biomedical sciences MTEC membership is not required for proposal submission, but it is required for an award.

View Solicitation

Topics: Therapeutic(s) that can treat COVID-19. Treatments with potential application to the prevention of COVID-19 infection are desired. Therapeutics that can be administered in a non-hospital environment are desired.

Enhanced White Paper Due Date: 4/8/2020
Budget: Up to $5,000,000

Coalition for Epidemic Preparedness Innovation (CEPI)

Multi-purpose platform technologies for rapid response against emerging infectious diseases

View Solicitations

Topic: Vaccine and adaptive epidemic response platform development

Due Date: Expressions of Interest (EOIs) will be accepted on a rolling basis until 10/14/2020.
Budget: Not specified

Medical CBRN Defense Consortium (MCDC)

Request for Information (RFI) – CoV Pandemic Response

View Solicitation

MCDC is requesting proposals regarding rapidly deployable (1-6 months) products and technologies to combat the current pandemic.  Longer-term solutions are not requested in this RFI.

Topic: COVID-19-related Diagnostics/Monitoring, Surveillance, Information Systems for Point of Care, Therapeutics, Prophylactics, Clinical Trials

Due Date: 5/31/2020
Budget: Not Specified

American Heart Association (AHA)

AHA Rapid Response Grant

AHA is offering fast-tracked research grants for short-term projects that can turn around results within 9-12 months to better understand the diagnosis, prevention, treatment and clinical management of COVID-19 as it relates to heart and brain health.

View Solicitation

Topics: Cardiovascular and cerebrovascular pathogenesis, diagnosis, prevention, clinical manifestations, clinical management (including critical care management) and social behaviors which can lead to dissemination, containment, and complications of COVID-19.

Due Date: 4/6/2020
Budget: $100,000

Amazon Web Services (AWS)

AWS Diagnostic Development Initiative (DDI)

View Solicitation

Topics: Using AWS to support research-oriented workloads for the development of point-of-care diagnostic (testing that can be done at home or at a clinic with same-day results) and other diagnostic techniques.  Initial emphasis will be on COVID-19, but other infectious disease diagnostic projects will be considered.

Due Date: Submissions accepted until 6/30/2020. Funding decisions will be made within 45 days of submission.
Budget: Awards will consist of promotional credits to be put toward AWS resource usage.

VI. International Opportunities

Novo Nordisk Foundation (Denmark)

View Application Information (Danish)

Eligibility: Public or private institutions in Denmark


  • Scientific projects that test new treatments, techniques and technologies or preventive initiatives that can rapidly be used to manage the challenges the health system faces in the current situation;
  • Information and outreach initiatives that can improve the communication to the public and their understanding and knowledge about how the health aspects of the crisis are being managed; and
  • Social initiatives designed to meet the special health needs of vulnerable groups affected by the crisis.

Budget: Up to DDK 5 million
Due Date: Applications accepted through 6/18/2020
Note: Application turnaround time is ~48 hours

Israel Innovation Authority

Call for Proposals for R&D Plans of Industrial Products for the Prevention and Treatment of the COVID-19 (Coronavirus)

View Solicitation

Topic: R&D plans submission may include the development of products, raw materials, innovative technologies and manufacturing processes, practical demonstrations, development of prototypes in the final stages of R&D or developing a scaling process for the transition from experimental production to mass-production.

Due Date: Multiple due dates through 5/18/2020
Budget: 30% to 70% of R&D costs will be supported.

Share New Opportunities

If you are aware of other COVID-19 research grants, we would appreciate you letting us know.
Click here to send us an email.